Hypomagnesemia

Hypomagnesemia
Classification and external resources

Magnesium
ICD-10 E83.4
ICD-9 275.2
DiseasesDB 6469
MedlinePlus 000315
eMedicine med/3382 emerg/274 ped/1122

Hypomagnesemia (or hypomagnesaemia) is an electrolyte disturbance in which there is an abnormally low level of magnesium in the blood.[1] Normal magnesium levels in humans fall between 1.5 - 2.5 mg/dL. Usually a serum level less than 0.7 mmol/L is used as reference for hypomagnesemia (not hypomagnesia which refers to low magnesium content in food/supplement sources). The prefix hypo- means low (contrast with hyper-, meaning high). The middle 'magnes' refers to magnesium. The end portion of the word, -emia, means 'in the blood.'

Hypomagnesemia is not equal to magnesium deficiency. Hypomagnesemia can be present without magnesium deficiency and vice versa. Note, however, that hypomagnesemia is usually indicative of a systemic magnesium deficit.

Hypomagnesemia may result from a number of conditions including inadequate intake of magnesium, chronic diarrhea, malabsorption, alcoholism, chronic stress, and medications such as diuretics use among others.

Contents

Signs and symptoms

Deficiency of magnesium causes weakness, muscle cramps, cardiac arrhythmia, increased irritability of the nervous system with tremors, athetosis, jerking, nystagmus and an extensor plantar reflex. In addition, there may be confusion, disorientation, hallucinations, depression, epileptic fits, hypertension, tachycardia and tetany.

Causes

Magnesium deficiency is not uncommon in hospitalized patients. Elevated levels of magnesium (hypermagnesemia), however, are nearly always iatrogenic. Ten to twenty percent of all hospital patients and 60–65% of patient in the intensive care unit (ICU) have hypomagnesemia. Hypomagnesemia is underdiagnosed, as testing for serum magnesium levels is not routine.

Low levels of magnesium in blood may mean that there is not enough magnesium in the diet, the intestines are not absorbing enough magnesium, or the kidneys are excreting too much magnesium. Deficiencies may be due to the following conditions:

Drugs

Medications

Pathophysiology

Homeostasis

The body contains 21–28 grams of magnesium (0.864–1.152 mol). Of this, 53% is located in bone, 19% in non-muscular tissue, and 1% in extracellular fluid. For this reason, blood levels of magnesium are not an adequate means of establishing the total amount of available magnesium. Most of the serum magnesium is bound to chelators, (i.e. ATP, ADP, proteins and citrate). Roughly 33% is bound to proteins, and 5–10% is not bound. This "free" magnesium is essential in regulating intracellular magnesium. Normal plasma Mg is 1.7–2.3 mg/dl (0.69–0.94 mmol/l). Of this 60% is free, 33% is bound to proteins, and less than 7% is bound to citrate, bicarbonate and phosphate.

Magnesium is abundant in nature. It can be found in green vegetables, chlorophyll, cocoa derivatives, nuts, wheat, seafood, and meat. It is absorbed primarily in the duodenum of the small intestine. The rectum and sigmoid colon can absorb magnesium. Hypermagnesemia has been reported after enemas containing magnesium. Forty percent of dietary magnesium is absorbed. Hypomagnesemia stimulates and hypermagnesemia inhibits this absorption.

The kidneys regulate the serum magnesium. About 2400 mg of magnesium passes through the kidneys, of which 5% (120 mg) is excreted through urine. The loop of Henle is the major site for magnesium homeostasis, and 60% is resorbed.

Magnesium homeostasis comprises three systems: kidney, small intestine, and bone. In the acute phase of magnesium deficiency there is an increase in absorption in the distal small intestine and tubular resorption in the kidneys. When this condition persists, serum magnesium drops and is corrected with magnesium from bone tissue. The level of intracellular magnesium is controlled through the reservoir in bone tissue.

Metabolism

Magnesium is a cofactor in more than 300 enzyme-regulated reactions, most importantly forming and using ATP, i.e., kinase.[6] There is a direct effect on sodium (Na), potassium (K), and calcium (Ca) channels. It has several effects:

Diagnosis

The diagnosis can be made by finding a plasma magnesium concentration of less than 0.7 mmol/l. Since most magnesium is intracellular, a body deficit can be present with a normal plasma concentration. In addition to hypomagnesemia, up to 40% cases will also have hypocalcemia while in up to 60% of cases, hypokalemia will also be present. The ECG shows a prolonged QT interval.

Treatment

Treatment of hypomagnesemia depends on the degree of deficiency and the clinical effects. Oral replacement is appropriate for patients with mild symptoms, while intravenous replacement is indicated for patients with severe clinical effects.[9]

Numerous magnesium dietary supplements are available. Magnesium oxide, one of the most common because it has high magnesium content per weight, has been reported to be the least bioavailable.[10][11] Magnesium citrate has been reported as more bioavailable than oxide or amino-acid chelate (glycinate) forms.[12]

Intravenous magnesium sulfate (MgSO4) can be given in the following conditions:

Arrhythmia

Magnesium is needed for the adequate function of the Na+/K+-ATPase pumps in the cells of the heart. A lack of it depolarizes and results in tachyarrhythmia. Magnesium inhibits release of potassium, a lack of magnesium increases loss of potassium. Intracellular levels of potassium decrease and the cells depolarize. Digoxin increases this effect. Both digoxin and hypomagnesemia inhibit the Na-K pump resulting in decreased intracellular potassium.

Magnesium intravenously helps in refractory arrhythmia, most notably torsade de pointes.[9] Others are ventricular tachycardia, supraventricular tachycardia and atrial fibrillation.[13]

The effect is based upon decreased excitability by depolarization and the slowing down of electric signals in the AV-node. Magnesium is a negative inotrope as a result of decrease calcium influx and calcium release from intracellular storage. It is just as effective as verapamil. In myocardial infarction there is a functional lack of magnesium, supplementation will decrease mortality.[13]

Obstetric

Most importantly pre-eclampsia. It has an indirect antithrombotic effect upon thrombocytes and the endothelial functions (increase in prostaglandin, decrease in thromboxane, decrease in angiotensin II), microvascular leakage and vasospasm through its function similar to calcium channel blockers.

Convulsions are the result of cerebral vasospasm. The vasodilatatory effect of magnesium seems to be the major mechanism.

Electrolyte disturbances

Pulmonary

Acute asthma: here there is a bronchodilatatory effect, probably by antagonizing a calcium-mediated constriction.[14] Also, adrenergic stimulation, i.e. sympatheticomimetics used for treatment of asthma, might lower serum levels of magnesium, which must therefore be supplemented.

See also

References

  1. ^ "hypomagnesemia" at Dorland's Medical Dictionary
  2. ^ a b Whang R, Hampton EM, Whang DD (1994). "Magnesium homeostasis and clinical disorders of magnesium deficiency". Ann Pharmacother 28 (2): 220–6. PMID 8173141. 
  3. ^ http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm
  4. ^ Sheen, E; Triadafilopoulos, G (2011 Apr). "Adverse effects of long-term proton pump inhibitor therapy.". Digestive diseases and sciences 56 (4): 931–50. PMID 21365243. 
  5. ^ Chareonpong-Kawamoto N, Yasumoto K (1995). "Selenium deficiency as a cause of overload of iron and unbalanced distribution of other minerals". Biosci. Biotechnol. Biochem. 59 (2): 302–6. doi:10.1271/bbb.59.302. PMID 7766029. 
  6. ^ a b al-Ghamdi SM, Cameron EC, Sutton RA (1994). "Magnesium deficiency: pathophysiologic and clinical overview". Am. J. Kidney Dis. 24 (5): 737–52. PMID 7977315. 
  7. ^ Sihler, KC; Napolitano, LM (2010 Jan). "Complications of massive transfusion.". Chest 137 (1): 209–20. PMID 20051407. 
  8. ^ Huang, CL, Kuo E (2007). "Mechanism of Hypokalemia in Magnesium Deficiency". J Am Soc Nephrol. 18 (10): 2649–2652. doi:10.1681/ASN.2007070792. PMID 17804670. 
  9. ^ a b Durlach J, Durlach V, Bac P, Bara M, Guiet-Bara A (1994). "Magnesium and therapeutics". Magnes Res 7 (3–4): 313–28. PMID 7786695. 
  10. ^ Firoz M, Graber M (2001). "Bioavailability of US commercial magnesium preparations". Magnes Res 14 (4): 257–62. PMID 11794633. 
  11. ^ Lindberg JS, Zobitz MM, Poindexter JR, Pak CY (1990). "Magnesium bioavailability from magnesium citrate and magnesium oxide". J Am Coll Nutr 9 (1): 48–55. PMID 2407766. 
  12. ^ Walker AF, Marakis G, Christie S, Byng M (2003). "Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study". Magnes Res 16 (3): 183–91. PMID 14596323. http://www.john-libbey-eurotext.fr/medline.md?issn=0953-1424&vol=16&iss=3&page=183. 
  13. ^ a b Ramsay JG (1999). "Cardiac management in the ICU". Chest 115 (5 Suppl): 138S–144S. doi:10.1378/chest.115.suppl_2.138S. PMID 10331347. http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=10331347. 
  14. ^ Mills R, Leadbeater M, Ravalia A (1997). "Intravenous magnesium sulphate in the management of refractory bronchospasm in a ventilated asthmatic". Anaesthesia 52 (8): 782–5. doi:10.1111/j.1365-2044.1997.176-az0312.x. PMID 9291766. 

External links